Increase compound collection value and diversity through collaborations, partnerships, and open-innovation
Pharmaceutical R&D is facing increasing pressure such as rising operational costs, depleted pipelines and patent expiries.
In this environment, it is crucial to improve R&D productivity. This can be achieved by increasing the level of collaboration and partnership between pharmaceutical companies, academia and CROs. Some examples of such collaborations related to the increase of the size and the quality of the AstraZeneca screening collection will be presented as well as details on the cheminformatics platform supporting these activities.